• GeneWorks is a leading life science distributor focused on molecular and cell biology
• Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing (NGS) and single cell analysis (SCA) applications
Madrid, Spain and Heidelberg, Germany, August 25 th , 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio in Australia with GeneWorks Pty Ltd.
Under the terms of the agreement, SYGNIS has granted GeneWorks the rights to promote, market and sell all existing as well as future products including the Company’s revolutionary TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in genomics, proteomics and diagnostics in Australia.
GeneWorks is a specialist provider offering a broad portfolio of innovative research reagents in the field of molecular biology as well as cell biology applications to customers in Australia.
"We are very pleased about the distribution agreement with GeneWorks for the Australian continent, which significantly strengthens our worldwide presence and perfectly positions our products in the rapidly growing biotechnology industry,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Over the recent months we experienced an increasing demand in our proprietary product and technology families, fueled by our extensive marketing activities and ongoing efforts to further expand our distribution network in order to make our portfolio widely available for researchers working in the life science industry throughout the world."
Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered through SYGNIS’ own online shop under http://www.sygnis.com/shop.
About TruePrime™
TruePrime TM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime TM is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
About SunScript™ RT
SunScript TM RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript TM Reverse Transcriptase will be available in two versions: SunScript TM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScript TM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi ® , licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
Help employers find you! Check out all the jobs and post your resume.
• Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing (NGS) and single cell analysis (SCA) applications
Madrid, Spain and Heidelberg, Germany, August 25 th , 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio in Australia with GeneWorks Pty Ltd.
Under the terms of the agreement, SYGNIS has granted GeneWorks the rights to promote, market and sell all existing as well as future products including the Company’s revolutionary TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in genomics, proteomics and diagnostics in Australia.
GeneWorks is a specialist provider offering a broad portfolio of innovative research reagents in the field of molecular biology as well as cell biology applications to customers in Australia.
"We are very pleased about the distribution agreement with GeneWorks for the Australian continent, which significantly strengthens our worldwide presence and perfectly positions our products in the rapidly growing biotechnology industry,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Over the recent months we experienced an increasing demand in our proprietary product and technology families, fueled by our extensive marketing activities and ongoing efforts to further expand our distribution network in order to make our portfolio widely available for researchers working in the life science industry throughout the world."
Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered through SYGNIS’ own online shop under http://www.sygnis.com/shop.
About TruePrime™
TruePrime TM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime TM is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
About SunScript™ RT
SunScript TM RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript TM Reverse Transcriptase will be available in two versions: SunScript TM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScript TM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi ® , licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
Help employers find you! Check out all the jobs and post your resume.